Paclitaxel, carboplatin plus gemcitabine (PCG) as first-line treatment for advanced epithelial ovarian cancer (EOC): Pathologic complete response (pCR) and impact on cognitive functioning

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5016-5016
Author(s):  
M. L. Hensley ◽  
D. Correa ◽  
H. Thaler ◽  
A. Wilton ◽  
E. Venkatraman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cognitive Functioning ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Line Treatment ◽  
First Line ◽  
Advanced Epithelial Ovarian Cancer ◽  
First Line Treatment

Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer

1995 ◽  
Vol 5 (6) ◽  
pp. 443-448 ◽  
Author(s):  
D. Z. Edelmann ◽  
T. Peretz ◽  
V. Barak ◽  
S. O. Anteby
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Performance Status ◽  
Survival Rates ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Chemotherapeutic Agents ◽  
Synergistic Activity ◽  
First Line ◽  
Advanced Epithelial Ovarian Cancer

Carboplatin and etoposide are chemotherapeutic agents active in ovarian cancer, previously proved to have a synergistic activity in animal models. The objective of this phase II study was to determine the feasibility and the efficacy of the combination of carboplatin and etoposide in previously untreated patients with advanced epithelial ovarian cancer.Carboplatin, 400 mg m−2 day 1, and etoposide, 100 mg m−2 days 1–3 every 4 weeks were administered to 28 patients with advanced stage (III–IV) ovarian cancer and a performance status 0–2 (ECOG scale), as a firstline chemotherapy.Twenty-three patients were evaluable for response; 15 (65%) (95% CI: 45–81%) responded, 10 (43%) (95% CI: 25–63%) with clinical complete response. Pathologic complete response demonstrated during postchemotherapy laparotomy was noted in 5/23 (22%) (95% CI: 9–42%) patients. The median progression-free interval was 8.5 months, and median survival was 19.5 months. Toxicity, mainly hematologic, was severe. Nine (32%) patients experienced at least one episode of leucopenic fever, which consequently led to toxic deaths in two (7%) patients.The relatively low response and survival rates with increased toxicity rate are disappointing.

Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer.

2017 ◽  
Vol 53 (3) ◽  
pp. 139-146
Author(s):  
Urszula Rychlik ◽  
Ewa Wójcik ◽  
Jadwiga Tarapacz ◽  
Katarzyna Brandys ◽  
Zofia Stasik ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Complete Response ◽  
Response To Treatment ◽  
Line Treatment ◽  
First Line ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio ◽  
Progression Of Disease ◽  
First Line Treatment

Introduction: The aim of the study was to assess the prognostic value of indicators calculated on the basis of initial hematology test results of neutrophil, lymphocyte, monocyte and platelet counts (NLR – neutrophil-to-lymphocyte ratio, LMR – lymphocyte-to-monocyte ratio, PLR – platelet-to-lymphocyte ratio) in patients with ovarian cancer and their compliance with the overall response to treatment. Materials and methods: Hematological tests were performed before first course of first-line chemotherapy in 145 patients with ovarian cancer. Response to treatment was assessed according to the RECIST1.1 criteria in all patients. Results: After the completion of first-line treatment, 70 (48.3%) patients had a complete response (CR) to the therapy. In this group, progression of disease occurred in 22 (31.4%) patients during 12 months of follow-up. In the CR group with progression, 17 (77.2%) presented high NLR and PLR levels. Among 48 (68.6%) patients with CR without progression after 12 months of follow-up, high levels of NLR and PLR were observed in 21 (43.8%) and 17 (35.4%) of them, respectively. Low LMRs were observed in 16 (72.7%) patients with progression and 16 (33.3%) without progression. Conclusion: High levels of NLR and PLR and low levels of LMR before treatment seems to predict 12-month disease progression in patients with complete response to first-line treatment.

P168 Influence of first-line treatment for epithelial ovarian cancer on the immune system

2019 ◽  
Author(s):  
T Baert ◽  
C Landolfo ◽  
J Ceusters ◽  
G Thirion ◽  
A Van Hoylandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document